Hottenrott, Tilman http://orcid.org/0000-0001-5216-0960
Schorb, Elisabeth
Fritsch, Kristina
Dersch, Rick
Berger, Benjamin
Huzly, Daniela
Rauer, Sebastian
Tebartz van Elst, Ludger
Endres, Dominique
Stich, Oliver
Article History
Received: 11 November 2017
Revised: 29 January 2018
Accepted: 30 January 2018
First Online: 6 March 2018
Compliance with ethical standards
:
: The ethics committee of the University Freiburg approved the study (EK-Fr 489/14).
: Not applicable.
: The data that support the findings of this study are included in this study or available from the corresponding author upon reasonable request.
: TH received travel grants from Bayer Vital GmbH and Novartis. ES, KF, RD and DE report no conflicts of interest with this study. BB received travel grants and/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Norvartis, and Genzyme, as well as lecture fees from Ipsen Pharma GmbH. DH received lecture fees from Serion. LTvE received consulting and lecture fees, grant and research support from Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen, and Cyberonics. OS and SR report receiving consulting and lecture fees, grant and research support from Baxter, Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, RG, Sanofi-Aventis and Teva. Furthermore, SR indicates that he is a founding executive board member of ravo Diagnostika GmbH (Oltmannsstraße 5, D-79100 Freiburg, Germany), which is selling in vitro diagnostic medical devices for the detection of infectious diseases and paraneoplastic autoantibodies.
: All authors except OS are doctors working at the Medical Centre-University Freiburg, Germany; OS is working as a consultant physician at the medical care unit in Konstanz, Germany. TH, RD and DE are resident physicians; ES and KF are consultant physicians; BB and DH are senior physicians. SR and LTvE are chief physicians.